Table 1

Demographic features, cancer types and immunotherapy of included patients

Patient	Age	Sex	Race	Type of malignancy	Cancer therapy	Rheumatic IRAE	Best overall response (RECIST 1.1)
1	58	Male	Caucasian	Renal cell carcinoma	Anti-PD-1 Anti-CTLA-4	Inflammatory arthritis	Stable disease
2	46	Female	Caucasian	Melanoma	Anti-PD-1 Anti-CTLA-4	Inflammatory arthritis	Partial response
3	62	Male	African American	Non-small cell lung cancer	Anti-PD-1 Anti-CTLA-4	Inflammatory arthritis	Stable disease
4	35	Male	Caucasian	Melanoma	Anti-PD-1 Anti-CTLA-4	Inflammatory arthritis	Stable disease
5	56	Male	Caucasian	Non-small cell lung cancer	Anti-PD-1	Inflammatory arthritis	Stable disease
6	66	Male	Caucasian	Melanoma	Anti-PD-1 Anti-CTLA-4	Inflammatory arthritis	Partial response
7	57	Male	Caucasian	Small cell lung cancer	Anti-PD-1 Anti-CTLA-4	Inflammatory arthritis	Partial response
8	42	Male	Caucasian	Non-small cell lung cancer	Anti-PD-1 Anti-CTLA-4	Inflammatory arthritis	Partial response
9	75	Female	Caucasian	Non-small cell lung cancer	Anti-PD-1	Inflammatory arthritis	Partial response
10	61	Male	Caucasian	Non-small cell lung cancer	Anti-PD-1	Sicca syndrome	Stable disease
11	57	Male	Caucasian	Melanoma	Anti-PD-1 Anti-CTLA-4	Sicca syndrome	Progressive disease
12	74	Male	Caucasian	Melanoma	Anti-CTLA-4	Sicca syndrome	Partial response
13	74	Female	Caucasian	Melanoma	Anti-PD-1	Sicca syndrome	No measureable disease by RECIST; tumour regression observed on clinical exam

Age is at the time of initial rheumatological assessment.
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death protein 1.